Financial Contrast: Savara (NASDAQ:SVRA) versus Champions Oncology (NASDAQ:CSBR)

Champions Oncology (NASDAQ:CSBR) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Earnings and Valuation

This table compares Champions Oncology and Savara”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$56.94 million	1.47	$4.70 million	($0.16)	-37.56
Savara	N/A	N/A	-$118.84 million	($0.56)	-8.49

Champions Oncology has higher revenue and earnings than Savara. Champions Oncology is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Champions Oncology and Savara’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-3.94%	-57.31%	-7.51%
Savara	N/A	-87.19%	-66.42%

Insider & Institutional Ownership

41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 46.4% of Champions Oncology shares are held by company insiders. Comparatively, 5.3% of Savara shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility and Risk

Champions Oncology has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Savara has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Champions Oncology and Savara, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1	0	0	0	1.00
Savara	1	1	6	1	2.78

Savara has a consensus price target of $9.13, indicating a potential upside of 91.90%. Given Savara’s stronger consensus rating and higher probable upside, analysts plainly believe Savara is more favorable than Champions Oncology.

About Champions Oncology

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

About Savara

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.